ABSTRACT
Cytotoxic anti-tumor drugs are characterized by narrow therapeutic indexes, severe toxicity and great difference in the effects of individualized therapies, while studies of pharmacogenomics (PGx) can provide biomarkers for predicting the efficacy and toxicity of chemotherapy drugs. PGx biomarkers play an important role in predicting the safety, toxicity and effects of drugs in the treatment of tumors. By identifying specific polymorphisms of PGx biomarkers, physicians could select and customize medication regimens based on the patient's genetic profile. This review focuses on the germline PGx biomarkers that are currently used for guiding therapeutic decisions and have potential clinical application values, including thiopurine S-methyltransferase and thiopurine, NUDT15 and thiopurine, UGT1A1 and irinotecan, DPYD and fluorouracil, CYP2D6 and tamoxifen, and TPMP and cisplatin.